Inventor · disambiguated record
Elena Dneprovskaia
Also filed as: DNEPROVSKAIA ELENA · DNEPROVSKAIA ELENA V
14 granted patents·11 pending applications·193 citations·filing 2002–2024
92Inventor score
Files withTARGEGEN INC13ALTEROME THERAPEUTICS INC3ANTIDOTE IP HOLDINGS LLC2GONG XIANCHANG2PHENEX PHARMACEUTICALS AG2
Top patents by PatentIndex Score
25 records- 0191US11999730B1AKT1 modulatorsALTEROME THERAPEUTICS INC·Filed 2023·Granted Jun 4, 2024·2 cites·29 claims
- 0291US7652051B2Heterocyclic compounds and methods of useTARGEGEN INC·Filed 2005·Granted Jan 26, 2010·16 cites·15 claims
- 0391US7208493B2Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2003·Granted Apr 24, 2007·68 cites·9 claims
- 0487US7098336B2FXR NR1H4 nuclear receptor binding compoundsPHENEX PHARMACEUTICALS AG·Filed 2002·Granted Aug 29, 2006·18 cites·13 claims
- 0587US6974830B2NR1H4 nuclear receptor binding compoundsPHENIX PHARMACEUTICALS AG·Filed 2002·Granted Dec 13, 2005·32 cites·19 claims
- 0686US7691858B2Kinase inhibitors and methods of use thereofTARGEGEN INC·Filed 2007·Granted Apr 6, 2010·11 cites·7 claims
- 0785US8030487B22-amino—5-substituted pyrimidine inhibitorsTARGEGEN INC·Filed 2007·Granted Oct 4, 2011·10 cites·34 claims
- 0885US7456176B2Benzotriazine inhibitors of kinasesTARGEGEN INC·Filed 2005·Granted Nov 25, 2008·11 cites·34 claims
- 0982US8084618B2Heterocyclic compounds and methods of useWRASIDLO WOLFGANG·Filed 2010·Granted Dec 27, 2011·5 cites·17 claims
- 1082US7034046B2NR1H4 nuclear receptor binding compoundsPHENEX PHARMACEUTICALS AG·Filed 2002·Granted Apr 25, 2006·19 cites·7 claims
- 1179US2025092040A1Akt1 modulatorsALTEROME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1277US12209087B2AKT1 modulatorsALTEROME THERAPEUTICS INC·Filed 2024·Granted Jan 28, 2025·0 cites·20 claims
- 1372US8372971B2Heterocyclic compounds and methods of useTARGEGEN INC·Filed 2011·Granted Feb 12, 2013·1 cites·22 claims
- 1461US2010278811A1Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2009·Application pending·0 cites
- 1558US2013243754A1Heterocyclic compounds and methods of useTARGEGEN INC·Filed 2012·Application pending·0 cites
- 1656US2007161645A1Thiazole inhibitors targeting resistant kinase mutationsTARGEGEN INC·Filed 2006·Application pending·0 cites
- 1755US2005282814A1Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2005·Application pending·0 cites
- 1854US2007208019A1Vasculostatic agents and methods of use thereofTARGEGEN INC·Filed 2007·Application pending·0 cites
- 1954US2009275569A1Benzotriazine Inhibitors of KinasesGONG XIANCHANG·Filed 2008·Application pending·0 cites
- 2051US2007149508A1Six membered heteroaromatic inhibitors targeting resistant kinase mutationsTARGEGEN INC·Filed 2006·Application pending·0 cites
- 2146US2010330030A1Vasculostatic Agents and Methods of Use ThereofTARGEGEN INC·Filed 2010·Application pending·0 cites
- 2243US8481536B2Benzotriazine inhibitors of kinasesGONG XIANCHANG·Filed 2010·Granted Jul 9, 2013·0 cites·5 claims
- 2337US2007010562A1Nr1h4 nuclear receptor binding compoundsBAUER ULRIKE·Filed 2002·Application pending·0 cites
- 2435US12312337B2Compounds and methods for treating cancerANTIDOTE IP HOLDINGS LLC·Filed 2020·Granted May 27, 2025·0 cites·15 claims
- 2533US2020299282A1Compounds and methods for treating cancerANTIDOTE IP HOLDINGS LLC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elena Dneprovskaia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →